Document is current

Any future updates will be listed below

Cadonilimab is efficacious in HER2-negative advanced-stage G/GEJ adenocarcinomas

Crossref DOI link: https://doi.org/10.1038/s41571-025-00998-z

Published Online: 2025-02-07

Published Print: 2025-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark